We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...

HC Wainwright reiterated their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on ...

Exelixis (EXEL) announced that preclinical data will be presented for four pipeline molecules at the American Association for ...

Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Investment analysts at Leerink Partnrs increased their FY2026 EPS estimates for shares of Exelixis in a research note issued on Wednesday, March 26th.

Guggenheim analyst Michael Schmidt maintained a Buy rating on Exelixis (EXEL – Research Report) on March 26 and set a price target of $42.00.

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of ...

Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...

Exelixis (NasdaqGS:EXEL) saw an 11% share price increase over the last quarter, a period marked by significant achievements ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other most ...